Helus Pharma taps longtime CNS pharma leader Michael Cola as CEO

Boston and Toronto, February 10, 2026 (Globe Newswire) -- Helus Pharma named Michael Cola Chief Executive Officer, effective immediately, as the company shifts into a “scale and execution” phase. Cola previously led Shire’s Specialty Pharmaceutical business and brings 30+ years across neuroscience, rare disease, and specialty pharma, with experience spanning late-stage development and global commercialization. The company said the timing aligns with upcoming milestones, including expected Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 in Q4 2026, alongside an expanding IP estate of hundreds of patent filings.

Read full article here.